A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort.

CanAssist Breast (CAB), a prognostic test uses immunohistochemistry (IHC) approach coupled with artificial intelligence-based machine learning algorithm for prognosis of early-stage hormone-receptor positive, HER2/neu negative breast cancer patients. It was developed and validated in an Indian cohort. Here we report the first blinded validation of CAB in a multi-country European patient cohort.

Validation of CanAssist Breast immunohistochemistry biomarkers on an automated platform and its applicability in tissue microarray.

CanAssist Breast (CAB) is a prognostic test for early-stage hormone receptor-positive invasive breast cancer. The test involves performing immunohistochemical (IHC) analysis for five biomarkers, namely CD44, ABCC4, ABCC11, N-cadherin, and pan-cadherin. In addition to IHC grading information, three clinical features, i.

The usefulness of CanAssist breast in the assessment of recurrence risk in patients of ethnic Indian origin.

Accurate recurrence risk assessment in hormone receptor positive, HER2/neu negative breast cancer is critical to plan precise therapy. CanAssist Breast (CAB) assesses recurrence risk based on tumor biology using artificial intelligence-based approach. We report CAB risk assessment correlating with disease outcomes in multiple clinically high- and low-risk subgroups.

Androgen Receptor mRNA levels determine the prognosis in triple-negative breast cancer patients.

Background: Anti-Androgen Receptor (AR) therapy holds promise for a subset of AR expressing triple-negative breast cancer (TNBC) patients. However, current AR assays are suboptimal in detecting the dynamic range of AR expression, contributing to its controversial role in TNBC disease prognosis. This study is aimed at evaluating the feasibility of qRT-PCR to sensitively and robustly detect AR mRNA levels for prognostication.

Clinicopathological evaluation of nonmelanoma skin cancer.

Background: Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), in combination, are referred to as nonmelanoma skin cancers (NMSCs). NMSC is not as extensively studied in the Asian population as it is in the Caucasian population.

Aim: This study sought to evaluate the clinical and histopathologic aspects of NMSC from cases of cutaneous malignancies.